Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Gamida Cell's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-2.95 Mil. Gamida Cell's Total Assets for the quarter that ended in Dec. 2023 was $102.19 Mil.
Therefore, Gamida Cell's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was -0.03.
The historical rank and industry rank for Gamida Cell's Equity-to-Asset or its related term are showing as below:
GMDAQ'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.06 Med: 0.44 Max: 0.81
Current: -0.03
During the past 8 years, the highest Equity to Asset Ratio of Gamida Cell was 0.81. The lowest was -0.06. And the median was 0.44.
GMDAQ's Equity-to-Asset is ranked worse than 84.59% of 1564
companies
in the Biotechnology industry
Industry Median: 0.66
vs GMDAQ: -0.03
Gamida Cell Equity-to-Asset Historical Data
The historical data trend for Gamida Cell's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Gamida Cell's Equity-to-Asset
For the Biotechnology subindustry, Gamida Cell's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gamida Cell's Equity-to-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gamida Cell's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Gamida Cell's Equity-to-Asset falls into.
Gamida Cell Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Gamida Cell's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Gamida Cell Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Gamida Cell's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Gamida Cell Ltd is a clinical-stage biopharmaceutical company that is pioneering a diverse immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid tumors and blood cancers and other serious blood diseases. The company applies a proprietary expansion platform leveraging the properties of nicotinamide, or NAM, to allogeneic cell sources including umbilical cord blood-derived cells and natural killer, or NK, cells to create cell therapy candidates with the potential to redefine standards of care. Its primary product candidate is Omidubicel, an advanced cell therapy candidate for allogeneic hematopoietic stem cell transplant and GDA-201 is the company's lead investigational NK cell-based cancer immunotherapy product candidate.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GMDAQ has been successfully added to your 